DEFA14A: Premier to Go Private in $2.6B Patient Square Acquisition

Premier, Inc. has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital for $2.6 billion, with stockholders receiving $28.25 per share in cash.

Summary

• Premier, Inc. will be acquired by Premium Parent, LLC, an affiliate of Patient Square Capital, in an all-cash transaction.
• The transaction is valued at approximately $2.6 billion.
• Premier stockholders will receive $28.25 in cash for each share of Class A common stock.
• The merger consideration represents a 23.8% premium to Premier's 60-day volume-weighted average price as of September 5, 2025.
• Premier's Board of Directors unanimously approved the merger agreement.
• Outstanding stock options will be cancelled for no consideration.
• Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards granted before August 16, 2025, will be converted into cash based on the merger consideration.
• RSU and PSU awards granted on or after August 16, 2025, will be cancelled for no consideration.
• The transaction is expected to close by the first quarter of calendar year 2026, subject to stockholder and regulatory approvals.
• Upon completion, Premier's Class A Common Stock will be delisted from the NASDAQ Global Select Market and deregistered.
• The transaction is not subject to a financing condition.
• Premier will suspend the declaration and distribution of common stock dividends in future quarters.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant premium offered to shareholders, the unanimous board approval, and the strategic rationale for future growth under private ownership. The absence of a financing condition further de-risks the transaction for Premier's shareholders.

Positives

• Stockholders will receive a significant premium of 23.8% over the 60-day volume-weighted average price as of September 5, 2025.
• The transaction provides immediate and certain cash value to stockholders.
• Transitioning to private ownership is expected to enhance financial flexibility and provide additional resources to accelerate product portfolio advancement and tech-enablement.
• The acquisition is anticipated to allow Premier to capitalize on emerging opportunities and continue innovation in healthcare.
• The transaction is not subject to a financing condition, which reduces closing risk.
• Premier's Board of Directors unanimously approved the merger agreement, indicating strong internal support for the transaction.

Negatives

• Outstanding stock options will be cancelled for no consideration, potentially disadvantaging option holders.
• Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards granted on or after August 16, 2025, will be cancelled for no consideration, impacting recent award recipients.
• Premier's Class A Common Stock will be delisted from NASDAQ, removing public trading access and liquidity for investors.
• The company will suspend the declaration and distribution of common stock dividends in future quarters, affecting income-focused shareholders.

Risks

• Inability to consummate the merger within the anticipated time period, or at all, due to failure to obtain required regulatory approvals (e.g., HSR Act) or stockholder approval.
• Risk that any announcements relating to the merger could have adverse effects on the market price of Premier Class A Common Stock.
• Disruption from the merger making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and other business partners.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Risks related to disruption of Premier's current plans and operations or the diversion of management's attention from ongoing business operations due to the merger.
• Significant transaction costs associated with the merger.
• Risk of litigation and/or regulatory actions related to the merger or unfavorable results from currently pending or future litigation and proceedings.
• The possibility of a Material Adverse Effect occurring prior to closing, which could impact the transaction.

Future Outlook

The company anticipates that transitioning to private ownership will enhance financial flexibility and provide additional resources to accelerate the advancement and tech-enablement of its product portfolio, capitalize on emerging opportunities, and continue innovation in the rapidly evolving healthcare landscape. The transaction is expected to close by the first quarter of calendar year 2026.

Management Comments

• "We are pleased to have reached this agreement and delighted that Patient Square recognizes and is committed to enhancing Premiers integral role in the U.S. health care system." Richard Statuto, Premier's Board Chair.
• "The Board unanimously approved this transaction, after careful consideration of a wide range of strategic alternatives in recent years and consultation with our financial and legal advisors. We believe this transaction is in the best interests of Premier and its stockholders and, upon closing, will deliver immediate and certain value to our stockholders, while simultaneously providing the Company with access to additional capital that can accelerate the support and services provided to members and other customers during this critical time in health care." Richard Statuto, Premier's Board Chair.
• "Since going public in 2013, Premier has leveraged our access to capital to build unmatched supply chain expertise, world-class technology, and nationally recognized advisory capabilities that enable our members to continuously improve their cost, quality, and operational efficiencies." Michael J. Alkire, Premier's President and CEO.
• "Now, as the health care landscape continues to rapidly evolve, transitioning to private ownership will once again enhance the Companys financial flexibility and provide additional resources to accelerate the advancement and tech-enablement of our product portfolio, capitalize on emerging opportunities and continue pushing the envelope of innovation." Michael J. Alkire, Premier's President and CEO.
• "I am proud of everything our team has achieved and look forward to building on our progress as we continue delivering real results for our members, contracted suppliers, customers and other stakeholders." Michael J. Alkire, Premier's President and CEO.
• "We have long admired Premier as an innovator of essential services and products to its members, which are leading institutions and providers in the U.S. health care system. Our team sees tremendous opportunity for Premier to continue growing its differentiated portfolio in supply chain services, data and technology offerings, and consulting solutions that deliver value to patients, and we look forward to working closely with the team as a private company." Neel Varshney, M.D., Patient Square Founding Partner.

Industry Context

The announcement highlights the rapidly evolving healthcare landscape, where Premier, as a technology-driven healthcare improvement company, seeks to enhance its financial flexibility and accelerate product advancement and tech-enablement through private ownership. This move by Patient Square Capital, a dedicated healthcare investment firm, underscores the continued private equity interest in essential healthcare services, supply chain, data, technology, and consulting solutions that aim to improve patient care and operational efficiencies within the U.S. health care system.

Comparison to Industry Standards

• The acquisition premium of 23.8% over the 60-day volume-weighted average price is a strong indicator of value for shareholders, often exceeding typical premiums in similar take-private transactions in the healthcare sector.
• The strategic rationale of enhancing financial flexibility and accelerating tech-enablement through private ownership is a common theme in the healthcare industry, where companies face increasing pressure for innovation and efficiency amidst complex regulatory and market dynamics.
• Patient Square Capital's focus on growth-oriented healthcare companies aligns with broader private equity trends targeting sectors with strong underlying demand and opportunities for operational improvement and technological integration.

Management Changes

Corporate Governance

Legal Proceedings

• The filing highlights the risk of litigation and/or regulatory actions related to the merger or unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.
• Premier is required to promptly notify Parent of any stockholder litigation or claims against the Company or its representatives arising out of or relating to the merger.

Related Party Transactions

• The filing states that since June 30, 2024, there have been no contracts or transactions that would be required to be disclosed under Item 404 of Regulation S-K that have not been disclosed in the Company Reports filed as of the date of the agreement. No new related party transactions are specifically detailed in the context of the merger itself beyond the standard merger agreement terms.

Stakeholder Impact

• Shareholders: Will receive $28.25 per share in cash, representing a significant premium, but will lose future dividend income and public market liquidity.
• Employees: Continuing employees will receive no less than their current base salary/wage and annual target cash bonus opportunities for one year post-closing. Other benefits will be substantially comparable. Equity awards granted before August 16, 2025, will be cashed out, while those granted on or after that date will be cancelled for no consideration, potentially impacting recent award recipients.
• Customers/Members: The company expects to accelerate support and services, and advance its product portfolio and tech-enablement, potentially leading to improved offerings.
• Suppliers/Vendors: The company aims to maintain existing significant business relationships.
• Management: Current officers of Premier will continue as officers of the Surviving Corporation. Directors of Merger Sub will become directors of the Surviving Corporation.

Next Steps

• Premier will prepare and file a proxy statement on Schedule 14A with the SEC.
• Premier will convene a meeting of its stockholders to vote on the approval of the merger agreement.
• The parties will work to obtain necessary regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act.
• Upon closing, Premier's Class A Common Stock will be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.
• Premier will suspend the declaration and distribution of common stock dividends in future quarters.

Key Dates

Recommendation

The acquisition offers a substantial 23.8% premium over the recent trading price, providing immediate and certain cash value to shareholders. The unanimous board approval and the absence of a financing condition significantly de-risk the transaction, making it highly attractive for investors seeking a quick and profitable exit. The terms are favorable, and the likelihood of closing appears high.

Keywords

Premier Inc, Patient Square Capital, Merger, Acquisition, Healthcare Technology, Supply Chain, PINC, Private Equity, SEC Filing, Corporate Governance, Stockholder Approval, Regulatory Approval, Cash Transaction, Healthcare Improvement